TrialBlood2023

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.

Morie A Gertz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.